Session » Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2533

A Comparison of Pregnancy Outcomes before and after Lupus Diagnosis

9:00AM-11:00AM: Abstract Number: 2530

A Multicenter Evaluation of Obstetric and Maternal Outcome in Prospectively Followed Pregnant Patients with Confirmed Positivity for Antiphospholipid Antibodies (aPL)

9:00AM-11:00AM: Abstract Number: 2538

A Population-Based Assessment of Induced Abortions in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2516

Association Between Primary Sjögren’s Syndrome and Pregnancy Outcome: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2523

Characteristics and Outcomes of Prospectively-Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database

9:00AM-11:00AM: Abstract Number: 2513

Contraception Use Amongst Women Ages 18-45 Taking Known Teratogenic Medications in an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 2529

Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta

9:00AM-11:00AM: Abstract Number: 2512

Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women

9:00AM-11:00AM: Abstract Number: 2532

Disease Activity in Women with Systemic Lupus Erythematosus during Pregnancy and the First Year Post Partum

9:00AM-11:00AM: Abstract Number: 2518

Does the Cytokine Pattern, Including the IL23 – IL17 Immune Axis, Change in Pregnant Women with Psoriatic Arthritis?

9:00AM-11:00AM: Abstract Number: 2531

Hematologic Disorder during Pregnancy Associated with Adverse Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2522

High Risk of Flares during Pregnancy in Women with Rheumatoid Arthritis Who Discontinue Treatment with TNF Inhibitors at Conception

9:00AM-11:00AM: Abstract Number: 2535

Increased Direct Healthcare Costs in SLE Pregnancies

9:00AM-11:00AM: Abstract Number: 2534

Increased Risk of Allergic Conditions in Children Born to Women with SLE

9:00AM-11:00AM: Abstract Number: 2524

Longterm Follow-up of Children Born to Mothers with Chronic Arthritides and Exposed to Anti-TNF Alfa Agents during Pregancy and Breastfeeding: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 2515

MEK5/ERK5, a Lynchpin of Human Cardiac Fibroblast Transdifferentiation to a Scarring Phenotype in Autoimmune Congenital Heart Block

9:00AM-11:00AM: Abstract Number: 2527

Neonatal Outcome to Paternal Exposures with Anti-Rheumatic Therapy

9:00AM-11:00AM: Abstract Number: 2525

Patterns and Secular Trends in Use of Immunosuppressive Agents during Pregnancy in Women with Rheumatologic Conditions

9:00AM-11:00AM: Abstract Number: 2526

Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2521

Pregnancies in Patients with Long-Standing Rheumatoid Arthritis and Biologic DMARD Treatment: Course of Disease during Pregnancy and Pregnancy Outcomes

9:00AM-11:00AM: Abstract Number: 2519

Pregnancy in Psoriatic Arthritis: A Case Series

9:00AM-11:00AM: Abstract Number: 2537

Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators

9:00AM-11:00AM: Abstract Number: 2517

Primary Sjögren’s Syndrome and Pregnancy: Evolution of Thyroid Function, Xerostomia, Xerophthalmia and Salivary Test for Dental Caries Risk

9:00AM-11:00AM: Abstract Number: 2520

Psoriatic Arthritis Activity during Pregnancy and the Postpartum� Period

9:00AM-11:00AM: Abstract Number: 2514

Subclinical Reduced Ovarian Reserve in Adult Polymiositis Patients

9:00AM-11:00AM: Abstract Number: 2536

The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl

9:00AM-11:00AM: Abstract Number: 2528

Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].